Anika Therapeutics, Inc. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
Anika Therapeutics, Inc. (ANIK) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2026-07-29
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2026-03-31 was $0.00.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-09-30 was $0.06.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-06-30 was $0.05, a 68.75% decline year-over-year.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2025 was -$0.06.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2024 was -$3.23.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2023 was -$5.41.
- Anika Therapeutics, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2022 was -$1.17.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | -$0.06 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $0.06 10-Q · filed 2025-11-05 | $0.04 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.05 10-Q · filed 2026-07-29 | -$0.02 10-Q · filed 2026-07-29 | ||
| 2025-03-31 | -$0.06 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | -$3.23 10-K · filed 2026-03-03 | |||
| 2024-09-30 | -$1.91 10-Q · filed 2025-11-05 | -$1.91 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.16 10-Q · filed 2025-07-30 | -$0.01 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | -$0.18 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$5.41 10-K · filed 2026-03-03 | |||
| 2022-12-31 | -$1.17 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |